SCHEDULE: Lyell Immunopharma: Stakeholder Ups Stake to 12.3%

Innovative Cellular Therapeutics Holdings Limited has increased its beneficial ownership in Lyell Immunopharma, Inc. to 12.3% following the achievement of a development milestone.

Summary

• Innovative Cellular Therapeutics Holdings Limited (Reporting Person) has filed an amendment to its Schedule 13G, reporting an increase in its beneficial ownership of Lyell Immunopharma, Inc. common stock.
• The Reporting Person now beneficially owns 3,000,000 shares of common stock, representing approximately 12.3% of the class.
• This increase is due to the achievement of a development milestone under a License Agreement dated November 6, 2025, which entitled the Reporting Person to acquire an additional 1,100,000 shares.
• The Reporting Person is deemed to have acquired beneficial ownership of these additional shares on May 18, 2026, the date their right to receive them became fixed.
• The percentage is calculated based on 24,434,087 shares of Common Stock outstanding as of May 1, 2026, plus the 1,100,000 shares the Reporting Person became entitled to receive.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it indicates a significant investor's increased commitment and belief in the company's progress, evidenced by the achievement of a development milestone.

Positives

• Increased stake in Lyell Immunopharma, Inc. by Innovative Cellular Therapeutics Holdings Limited, indicating continued or growing confidence.
• Achievement of a development milestone under a License Agreement, suggesting progress in the underlying technology or product development.
• The Reporting Person now holds a significant stake (12.3%), which could lead to greater influence or strategic alignment.

Negatives

• The filing does not explicitly state any negative financial or operational results for Lyell Immunopharma, Inc.

Risks

• The filing does not explicitly detail current risks or future challenges for Lyell Immunopharma, Inc. or the Reporting Person.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Lyell Immunopharma, Inc. The information pertains to a change in beneficial ownership by a third party.

Management Comments

• "This Amendment is being filed to report that, on May 18, 2026, upon the achievement of a development milestone under the License Agreement, dated November 6, 2025, between the Issuer and the Reporting Person, the Reporting Person became entitled to receive, and acquired the right to acquire, an additional 1,100,000 shares of Common Stock."
• "The Reporting Person is deemed to have acquired beneficial ownership of such shares on the date its right to receive them became fixed, thereby increasing the Reporting Person's aggregate beneficial ownership to 3,000,000 shares of Common Stock (approximately 12.3% of the class) and causing the Reporting Person to beneficially own more than 10% of the outstanding Common Stock."

Industry Context

StockSavvy.ai notes that an increase in beneficial ownership by a significant entity like Innovative Cellular Therapeutics Holdings Limited, especially following a development milestone, can signal positive momentum or strategic alignment within the biotechnology sector, particularly in areas like cell therapy where development progress is critical.

Related Party Transactions

• The filing details a License Agreement between Lyell Immunopharma, Inc. and Innovative Cellular Therapeutics Holdings Limited, dated November 6, 2025, under which a development milestone was achieved, leading to the acquisition of additional shares.

Stakeholder Impact

• Shareholders: May view the increased stake by a significant investor as a positive signal of confidence in the company's future prospects.
• Management of Lyell Immunopharma: May benefit from the increased strategic alignment and potential support from a larger shareholder.
• Innovative Cellular Therapeutics Holdings Limited: Has increased its investment and potential influence in Lyell Immunopharma.

Next Steps

• The Reporting Person will continue to hold its beneficial ownership of 3,000,000 shares of Lyell Immunopharma, Inc. common stock.
• Further developments related to the License Agreement and the achievement of subsequent milestones may occur.

Key Dates

Recommendation

The filing indicates a significant investor increasing their stake due to a development milestone, which is positive. However, it's a Schedule 13G amendment and doesn't provide Lyell Immunopharma's own operational or financial performance details. Therefore, while positive, it warrants a 'hold' recommendation pending further company-specific performance data.

Keywords

Lyell Immunopharma, Innovative Cellular Therapeutics Holdings Limited, Schedule 13G, Beneficial Ownership, Common Stock, Cayman Islands, License Agreement, Development Milestone, SEC Filing